Vitalis Therapeutics Inc. — The Target Product Profile for VitaFlow (VTX-401) at version v3.0: the label the program intends to earn, the minimum position below which it is not worth launching, and where each attribute stands at 15 October 2026.
1. What This Document Is
A Target Product Profile is the label Vitalis Therapeutics Inc. intends to earn for VitaFlow (VTX-401), written in the form the eventual label will take, and fixed before the evidence exists to support it. Every study in the development program is designed to produce evidence for a line in the table at §3.
It carries two columns rather than one. The target label is what the program is trying to achieve. The minimum acceptable is the position below which the product is not commercially or clinically worth launching. The gap between them is the program's room to manoeuvre, and stating it in advance is what stops the minimum from being quietly redefined as whatever the data eventually delivered.
2. Molecule & Mechanism
VTX-401 is a long-acting GLP-1 receptor agonist, a new molecular entity, administered as a once-weekly subcutaneous injection from a single-use prefilled pen.
GLP-1 receptor agonism reduces body weight through two mechanisms that operate together: delayed gastric emptying and central appetite suppression via hypothalamic receptor engagement. Both are well characterized across the class, and neither is where this program claims novelty.
The claim is in the receptor engagement profile. VTX-401 was selected at Gate 0 on preclinical evidence of a wider therapeutic window — efficacy at exposures below the threshold at which gastrointestinal tolerability degrades. If that separation holds in humans at scale, the product is differentiated. If it does not, the product is a me-too entering a crowded class late, and the program's own risk register says so: R-01 and R-02 are the two High-severity risks and both are clinical.
Regulatory pathway is 505(b)(1) New Drug Application — new molecular entity, per Decision D-01. No listed drug is referenced. Standard review, 10-month PDUFA goal from filing acceptance (A-02).
3. Target Product Profile — v3.0
Ten attributes. 5 on target, 2 carrying risk or concession, the remainder generating evidence.
| Attribute | Target label | Minimum acceptable | Position at Oct 2026 | Status |
|---|---|---|---|---|
| Indication | Chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity | BMI ≥30 only | Both populations enrolled in the pivotal program | on-target |
| Mean weight reduction, 68 weeks | ≥15% from baseline | ≥10% from baseline | Phase 2 delivered 12.4% at 36 weeks on the selected dose; the pivotal is powered for the target at 68 weeks | on-target |
| Responder rate (≥5% reduction) | ≥80% of participants | ≥65% | Phase 2 delivered 76% at 36 weeks; a co-primary endpoint in the pivotal program | on-target |
| Dosing interval | Once weekly, maintenance reached within 16 weeks of escalation | Once weekly, maintenance within 20 weeks | Escalation extended to 20 weeks after Phase 2 — the target was traded for tolerability. Approved products in the class escalate over 16 to 20 weeks. | conceded |
| GI-attributed discontinuation | ≤4% through 68 weeks | ≤7% | Phase 2 delivered 5.1% at 36 weeks. The differentiation claim rests here. | at-risk |
| Cardiovascular safety | No increased risk demonstrated; MACE hazard ratio upper bound <1.4 | No signal identified | CV outcomes sub-study running under CR-02; added on agency expectation at the End-of-Phase-2 meeting | in-progress |
| Presentation | Single-use prefilled pen, no reconstitution, 28 days at room temperature | Prefilled pen, refrigerated throughout | Pen confirmed; room-temperature stability data generating under the ICH protocol | in-progress |
| Shelf life | 24 months at 2–8°C plus 28 days in use at room temperature | 24 months at 2–8°C | Registration-batch stability on protocol; claim supportable at 18 months to date | in-progress |
| Risk management | No REMS at approval | No REMS at approval | Position held (D-07); safety database does not support one | on-target |
| Labeling | Class labeling only — boxed warning for thyroid C-cell tumours | Class labeling only | Consistent with approved products in the class | on-target |
If that figure holds or improves through the pivotal program, the product has a genuine position. If it drifts toward the class benchmark, VitaFlow is a late entrant to a crowded market with nothing distinguishing it. Everything else in this profile is secondary to that one number.
4. Presentation & Administration
Single-use prefilled pen, once weekly, subcutaneous. No reconstitution and no dose preparation by the patient.
The room-temperature stability claim — 28 days in use — is a commercial target rather than a clinical one, and it matters more than it looks. A product requiring continuous refrigeration constrains travel, complicates pharmacy handling and creates a compliance failure mode that has nothing to do with the molecule. The claim depends on registration-batch stability data now generating under the ICH protocol; the minimum acceptable position is a fully refrigerated presentation, which would be a real but survivable commercial loss.
An oral formulation is out of scope at launch (Decision D-02). Bioavailability work would have added an estimated eighteen months and a second CMC program for a segment the launch case does not require. It is deferred, not abandoned, and sits in the lifecycle candidate set at §7.
5. How the Profile Has Changed
The TPP is a living document under change control. Three versions, each fixed at a gate.
| Version | Fixed at | Date | What moved |
|---|---|---|---|
| v1.0 | Gate 0 | 01 Mar 2022 | Initial profile at candidate selection. Weight-reduction target set at ≥12%; GI discontinuation target set at ≤6%. |
| v2.0 | Gate 3 | 31 May 2024 | Weight target raised to ≥15% and GI discontinuation tightened to ≤4% on Phase 1 PK and early tolerability. Raising a target mid-program is unusual; it was done because the data supported a stronger claim than the profile was asking for. |
| v3.0 | Gate 4 | 30 Jun 2026 | Cardiovascular endpoint added following the End-of-Phase-2 meeting (CR-02). Responder rate fixed as a co-primary. Dosing-interval target relaxed from 4-week to 8-week escalation — the only target ever conceded, traded deliberately for tolerability. |
v3.0 records the program's only concession. The dosing-interval target was relaxed from a four-week to an eight-week escalation schedule. That was a deliberate trade: a slower escalation improves tolerability, and tolerability is the differentiation claim. The program gave up convenience to protect the thing it is actually selling. It is recorded as a concession rather than a refinement, because that is what it was.
6. Class Obligations
Two positions are fixed by the class rather than chosen by the program.
Thyroid C-cell tumour labeling. Rodent carcinogenicity findings across GLP-1 receptor agonists have produced consistent boxed warning language for the class. VitaFlow will carry it. This is not a negotiating position and no program decision affects it.
No REMS proposed at filing (Decision D-07). The safety database does not support a Risk Evaluation and Mitigation Strategy, and volunteering one would impose a commercial disadvantage the evidence does not require. Approved products in the class carry no REMS. The program's position is that a REMS should be imposed by the agency on evidence if the agency concludes it is warranted — it should not be offered pre-emptively to appear cooperative.
7. Scope Boundaries
What this profile deliberately does not cover.
| Excluded | Decision | Status |
|---|---|---|
| Oral formulation | D-02 | Deferred — lifecycle candidate |
| European and Asia-Pacific marketing applications | D-03 | Deferred to Year 4+. The Phase 2 Asian cohort added under CR-01 supports a later filing but does not constitute one. |
| Cardiovascular risk reduction as an indication | — | The CR-02 sub-study establishes safety, not an efficacy claim. A CV indication would require its own outcomes trial, its own business case and its own Gate 0. |
| Adolescent population | — | Lifecycle candidate. No paediatric study is in scope; a paediatric study plan is a filing obligation, not a development activity here. |
| Obstructive sleep apnoea and other comorbidity indications | — | Lifecycle candidates. No budget or resource in this program. |
Each exclusion carries no cost line in the Program Budget. A lifecycle candidate that appears in a target profile without appearing in a budget is an aspiration being smuggled into scope, which is why the two documents are reconciled.
8. Traceability
Every attribute in §3 traces to the evidence that will support it and to the governance record that fixed it.
| Attribute | Evidence source | Fixed by |
|---|---|---|
| Indication and population | Pivotal program enrolment criteria | End-of-Phase-2 meeting, 19 May 2026 |
| Weight reduction and responder rate | Co-primary endpoints, both pivotal trials | Agreed with the agency at End-of-Phase-2; Gate 4 must-meet M3 |
| Dosing interval | Phase 2 dose-ranging and tolerability data | TPP v3.0 at Gate 4 — conceded |
| GI discontinuation | Pivotal safety database; monitored endpoint under DMC review | TPP v2.0 at Gate 3 |
| Cardiovascular safety | CR-02 outcomes sub-study | CR-02 approved 20 Apr 2026 |
| Presentation and shelf life | Registration-batch stability under ICH protocol | CMC plan; Gate 5 must-meet |
| REMS position and labeling | Integrated safety summary | Decision D-07 |
Full decision records live in the RAID Log; the gate criteria that test these attributes are in the Gate Decision Framework; the narrative of how the profile got here is in the Program Story.